According to uniQure's latest financial reports the company's current revenue (TTM) is $19 M. In 2022 the company made a revenue of $0.10 B a decrease over the years 2021 revenue that were of $0.52 B.The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Year | Revenue | Change |
---|---|---|
2023 (TTM) | $15.84 M | -85.12% |
2022 | $0.10 B | -79.68% |
2021 | $0.52 B | 1296.82% |
2020 | $37.51 M | 415.23% |
2019 | $7.28 M | -35.48% |
2018 | $11.28 M | -13.91% |
2017 | $13.1 M | -47.6% |
2016 | $25.01 M | 143.98% |
2015 | $10.25 M | 73.14% |
2014 | $5.92 M | 47.02% |
2013 | $4.02 M |
Company | Revenue | Revenue differencediff. | Country |
---|---|---|---|
Amgen AMGN | $29.53 B | 155,307.04% | ๐บ๐ธ USA |
Sanofi SNY | $50.51 B | 265,718.79% | ๐ซ๐ท France |
Sangamo Therapeutics
SGMO | $18.75 M | -1.30% | ๐บ๐ธ USA |
bluebird bio
BLUE | $21.72 M | 14.33% | ๐บ๐ธ USA |
BioMarin Pharmaceutical BMRN | $2.47 B | 12,906.60% | ๐บ๐ธ USA |
Avidity Biosciences RNA | $10.87 M | -42.80% | ๐บ๐ธ USA |